WO2001079176A1 - Procede de preparation de 3-[(1'-(alkoxycarbonyl)-3'-phenylpropyl)amino]-2-oxo-[1]-benzazepine et de ses derives - Google Patents
Procede de preparation de 3-[(1'-(alkoxycarbonyl)-3'-phenylpropyl)amino]-2-oxo-[1]-benzazepine et de ses derives Download PDFInfo
- Publication number
- WO2001079176A1 WO2001079176A1 PCT/IB2000/000478 IB0000478W WO0179176A1 WO 2001079176 A1 WO2001079176 A1 WO 2001079176A1 IB 0000478 W IB0000478 W IB 0000478W WO 0179176 A1 WO0179176 A1 WO 0179176A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- halide
- carbon atoms
- alkyl group
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 title abstract description 21
- -1 amino acid ester Chemical class 0.000 claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims description 38
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- 125000004432 carbon atom Chemical group C* 0.000 claims description 17
- 238000006243 chemical reaction Methods 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 15
- 239000003444 phase transfer catalyst Substances 0.000 claims description 11
- 150000002431 hydrogen Chemical group 0.000 claims description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 8
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 230000002378 acidificating effect Effects 0.000 claims description 5
- 150000004820 halides Chemical class 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- 238000006555 catalytic reaction Methods 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims description 3
- GCFPFWRHYINTRX-UHFFFAOYSA-N 2-hydroxy-4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C(O)=C1 GCFPFWRHYINTRX-UHFFFAOYSA-N 0.000 claims description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 2
- 229960003872 benzethonium Drugs 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 229910052808 lithium carbonate Inorganic materials 0.000 claims description 2
- UJJUJHTVDYXQON-UHFFFAOYSA-N nitro benzenesulfonate Chemical compound [O-][N+](=O)OS(=O)(=O)C1=CC=CC=C1 UJJUJHTVDYXQON-UHFFFAOYSA-N 0.000 claims description 2
- 239000003880 polar aprotic solvent Substances 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 2
- QLAJNZSPVITUCQ-UHFFFAOYSA-N 1,3,2-dioxathietane 2,2-dioxide Chemical compound O=S1(=O)OCO1 QLAJNZSPVITUCQ-UHFFFAOYSA-N 0.000 claims 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 229910001507 metal halide Inorganic materials 0.000 claims 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 abstract description 7
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 abstract description 7
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 abstract description 7
- 230000006340 racemization Effects 0.000 abstract description 4
- 239000003112 inhibitor Substances 0.000 abstract description 3
- 239000007858 starting material Substances 0.000 abstract description 3
- 206010007558 Cardiac failure chronic Diseases 0.000 abstract description 2
- 206010020772 Hypertension Diseases 0.000 abstract description 2
- 208000020832 chronic kidney disease Diseases 0.000 abstract description 2
- 238000009833 condensation Methods 0.000 abstract description 2
- 230000005494 condensation Effects 0.000 abstract description 2
- 230000000750 progressive effect Effects 0.000 abstract description 2
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 7
- 229960004530 benazepril Drugs 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- NKZNPRQIONEKPT-UHFFFAOYSA-N n,n-dimethyl-1-quinolin-2-ylmethanamine Chemical compound C1=CC=CC2=NC(CN(C)C)=CC=C21 NKZNPRQIONEKPT-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- JMXPGCGROVEPID-UHFFFAOYSA-N 3-bromo-1,3,4,5-tetrahydro-1-benzazepin-2-one Chemical compound N1C(=O)C(Br)CCC2=CC=CC=C21 JMXPGCGROVEPID-UHFFFAOYSA-N 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical group [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 3
- HRVRAYIYXRVAPR-UHFFFAOYSA-N 1,3,4,5-tetrahydro-1-benzazepin-2-one Chemical class N1C(=O)CCCC2=CC=CC=C21 HRVRAYIYXRVAPR-UHFFFAOYSA-N 0.000 description 2
- 102000005862 Angiotensin II Human genes 0.000 description 2
- 101800000734 Angiotensin-1 Proteins 0.000 description 2
- 102400000344 Angiotensin-1 Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 0 CC(CCC1)*(C(*)=C)c2c1cccc2 Chemical compound CC(CCC1)*(C(*)=C)c2c1cccc2 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- AYJRCSIUFZENHW-UHFFFAOYSA-L barium carbonate Chemical compound [Ba+2].[O-]C([O-])=O AYJRCSIUFZENHW-UHFFFAOYSA-L 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N Caprolactam Natural products O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 1
- JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 108091008698 baroreceptors Proteins 0.000 description 1
- VPSRQEHTHIMDQM-FKLPMGAJSA-N benazepril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 VPSRQEHTHIMDQM-FKLPMGAJSA-N 0.000 description 1
- 229960003619 benazepril hydrochloride Drugs 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical class ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- SIAPCJWMELPYOE-UHFFFAOYSA-N lithium hydride Chemical compound [LiH] SIAPCJWMELPYOE-UHFFFAOYSA-N 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- FVPMMSKYNHPFOI-UHFFFAOYSA-M methyl sulfate;trimethyl(phenyl)azanium Chemical compound COS([O-])(=O)=O.C[N+](C)(C)C1=CC=CC=C1 FVPMMSKYNHPFOI-UHFFFAOYSA-M 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 210000001774 pressoreceptor Anatomy 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
Definitions
- the present invention relates to a process for the preparation of compounds which are useful in producing angiotensin-converting enzyme
- ACE ACE inhibitors.
- the process of the present invention is useful for preparing 3-[(r-(alkoxycarbonyl)-3'-phenylpropyl)ammo]-2-oxo-[ 1]- benzazepine and derivatives thereof.
- the present invention relates to a process for the preparation of 3- [(l'-(alkoxycarbonyl)-3'-phenylpropyl)amino]-2-oxo-[l]-benzazepine and derivatives thereof, which are useful in producing angiotensin-converting enzyme (ACE) inhibitors.
- ACE inhibitors are useful in the treatment of hypertension, chronic heart failure and progressive chronic renal insufficiency and which, by competing with angiotensin-converting enzyme for the substrate angiotensin I, block the conversion of angiotensin I to angiotensin II which is a potent vasoconstrictor and a negative-feedback mediator for renin activity.
- angiotensin II plasma levels are lowered, blood pressure decreases and plasma renin activity increases.
- baroreceptor reflex mechanisms are stimulated in response to the fall in blood pressure and the resistance against which the heart has to pump blood is lowered.
- U.S. Patent Nos. 4,410,520 and 4,575,503 disclose processes for the preparation of 3-amino-[l]-benzazepine-2-one-l-alkanoic acids.
- the processes are complex by either first bonding an amino group to the 1- position carbonyl group, or by attaching an amino group to the 3 '-position carbon with a good leaving group through a two-step reaction.
- the processes require several complex reaction steps, which may be more costly.
- a simpler and more efficient process for preparing 3-[(l'- (alkoxycarbonyl)-3 '-phenylpropyl)amiiio]-2-oxo-[ 1 ]-benzazepine- 1 -alkyl acids is required.
- the present invention discloses a novel process of directly bonding an amino acid ester to the 3-position carbon of 2,3,4,5-tetrahydro- lH-l-benzazepine-2-one derivatives which simplifies the production process.
- One object of the present invention is to provide processes for the preparation of 3-[(r-(alkoxycarbonyl)-3'-phenyl ⁇ ropyl)amino]-2-oxo ⁇ [l]- benzazepine and derivatives thereof.
- the processes of the present invention can avoid racemization and require fewer steps in the operational procedures than conventional methods. Furthermore, the processes of the present invention are overall more practical and economical than those of conventional processes.
- the present invention discloses a process for the preparation of a compound of the formula (I)
- is hydrogen, or a lower alkyl group having 1 to 4 carbon atoms
- R 2 is a lower alkyl group having 1 to 4 carbon atoms; and Xi is a hydrogen;
- Z is a halogen, reactive esterified hydroxy, tosylate, rrifluoromethane sulfonate, halogenated phenyl sulfonate, or nitro phenyl sulfonate; and X ⁇ is as defined above;
- Z 2 is a hydrogen; and Ri and R 2 are as defined above;
- phase transfer catalyst by catalysis of a phase transfer catalyst.
- the present invention discloses a novel process of using a non-natural amino acid ester, L-homophenylalanine alkyl ester or derivatives thereof, as a key starting material which can be produced and obtained in large quantities in condensation with a 3-halo-2,3,4,5-tetrahydro-lH-l- benzazepine-2-one which can also be obtained easily in large quantities, using catalysis of a phase transfer catalyst to produce a 3-[(l'- (alkoxycarbonyl)-3'-phenylpropyl)amino]-2-oxo-[ l]-benzazepine which can be easily transformed to a carboxylic acid thereof.
- L-homophenylalanine ethyl ester is ⁇ applied as the key starting material.
- the L-homophenylalanine ethyl ester is an optical pure compound and the chiral center at 1 -position can avoid racemization, which is proved by product optical rotation.
- the present invention further discloses a process for the preparation of a compound of the formula (IN)
- Ri is hydrogen, or a lower alkyl group having 1 to 4 carbon atoms
- R 2 is a lower alkyl group having 1 to 4 carbon atoms
- R 3 is an alkyl group having 1 to 6 carbon atoms, benzyl, or allyl group;
- R is a hydrogen, or a lower alkyl group having 1 to 4 carbon atoms
- n is an integral number ranging from zero to three;
- R 3 , R 4 and n are as defined above;
- X 2 is a halogen, reactive este ⁇ fied hydroxy, reactive sulfonate, tosylate or trifluoromethanesulfonate.
- the invention further discloses a process for the preparation of a compound of the formula (NI)
- Ri is hydrogen, or a lower alkyl group having 1 to 4 carbon atoms
- R 2 is a lower alkyl group having 1 to 4 carbon atoms
- ⁇ is a hydrogen, or a lower alkyl group having 1 to 4 carbon atoms
- n is an integral number ranging from zero to three;
- the process of the present invention provides a simpler and more efficient way of preparing 3-[(l'-(alkoxycarbonyl)-3'-phenylpropyl)amino]- 2-oxo-[l]-benzazepine-l-alkyl acids, and more particularly, benazepril.
- the process for the preparation of the compound of the formula (I) comprises reacting the compound of the formula (II) with the compound of the formula (III) by catalysis of a phase transfer catalyst.
- the compound of the formula (II), a derivative of 3-substituted-iT-caprolactam, or 3- substimted-2-3,4,5-tetrahydro-lH-.l-benzazepme-2-one can be prepared by a method analogous to that given in Helvetica Chimica Acta (page 337, vol. 71, 1988).
- the compound of formula (III) is a derivative of (+)-2-amino-4- phenylalkylic acid esters, or L-homophenylalanine alkyl esters.
- the compound of formula (III) is ethyl (+)-2-amino-4-phenylbutyric ester, or L-homophenylalanine ethyl ester.
- phase transfer catalysts can be used in the process according to the invention.
- the phase transfer catalysts may be chiral or nonchiral, and includes a tetra-alkylammonium halide, such as tetra-n-butylammonium halide, N-dodecyl-N-methyl-ephediinium halide, such as (-)-N-dodecyl-N-methyl- ephedrinium bromide, phenyltrimethylammonium halide, phenyltrimethylammonium methosulfate, benzyltrimethylammonium halide, N-benzylcinchoninium halide, benzyldimethyldodecylammonium halide or benzethonium halide.
- a tetra-alkylammonium halide such as tetra-n-butylammonium halide
- the reaction can be further catalyzed by using earth metal salts such as sodium iodide, lithium iodide and potassium iodide.
- the phase transfer catalyst is preferably tetra-n-butylammonium bromide.
- the reaction temperature is from 60 J to 1500 J, preferably from 90 J to HO J.
- the reaction can be carried out in a basic condition which is generally provided by a known base, such as sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, lithium carbonate, barium carbonate.
- a known base such as sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, lithium carbonate, barium carbonate.
- the solvents suitable for the process according to the invention can be N,N-dimethylacetamide (DMA), N,N-dimethylformamide (DMF), dimethylsulfoxide (DMSO), N-methylacetamide, acetonitrile, hexamethy .phosphoric rriamide, or any polar aprotic solvents.
- (rS,3S)-3-[(l'-(ethoxycarbonyl)-3'- phenylpropyl)amino]-2,3,4,5-tetrahydro-2-oxo-lH-benzazepine is prepared by reacting 3-bromo-2,3.4,5-tetrahydro-lH-l-benzazepine-2-one with (+)- L-homophenylalanine ethyl ester in the presence of a phase transfer catalyst.
- the preparation of the compound of the formula (IV) comprises a step of producing the compound of the formula (I) according to the above process and a step of condensing the compound of the formula (I) with a compound of the formula (V).
- the reaction is preferably carried out in the presence of a strong base such as sodium hydride, potassium hydride and lithium hydride.
- tert-butyl-(l'S,3S)-3-[( -(ethoxycarbonyl)-3'- phenylpropyl)amino]-2,3,4,5-tetrahydro-2-oxo-lH-benzazepine-l-acetate is produced by reacting (l'S,3S)-3-[(l'-(ethoxycarbonyl)-3'- phenylpropyl)amino]-2,3,4,5-tetrahydro-2-oxo-lH-benzazepme with t-butyl bromo acetate or t-butyl cbloro acetate in the presence of sodium hydride.
- the compound of the formula (IN) can be further reduced under an acidic condition to obtain a compound of formula (VI):
- the reaction is generally a hydrogenation or hydrolysis of the compound of the formula (IV).
- the acidic condition is provided by a known acid, such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, sulfurous acid and other inorganic or organic acids.
- benazepril i.e. 3 - [( 1 -(ethoxycarbonyl)-3 -phenyl-( 1 S)-propyl) amino] -2, 3 ,4, 5 -tetrahydro-2- oxo- lH-l-(3S)-benzazepine- l-acetic acid, is prepared by reducing the above tert-butyl-( S,3S)-3-[( -(ethoxycarbonyl)-3'-phenylpropyl)amino]-2,3,4,5- tetrahydro-2-oxo-lH-benzazepine-l -acetate in the presence of hydrochloric acid.
- Example 1
- 3-Bromo-2,3,4,5-tetrahydro-lH-l-benzazepine-2-one was prepared by a method analogous to that given in Helvetica Chimica Acta (page 337, vol. 71, 1988).
- Sodium bicarbonate (6.84 g), tetra-n-butyl ammonium bromide (TBAB, 1.191 g), 3-bromo-2,3,4,5-tetrahydro-lH-l-benzazepine- 2-one (17.68 g), and N, N-dimethylacetamide (40 ml) were subsequently added to a flask under nitrogen.
- L-homophenylalanine ethyl ester (L- HPAEE, 19.91 g) was mixed with N, N-dimethylacetamide (70 ml) and the mixture was then added to the flask. The mixture was stirred and heated to 1 1O J for 6 hours.
- the reaction mixmre was slowly added to 50 ml of water and extracted with 40 ml and 30 ml of ethylacetate respectively. The combined extracts were washed by water (35 ml) and brine (25 ml) and dried by magnesium sulfate for 30 minutes. The mixmre was filtered and dried under reduced pressure and brown oil (2.4 lg, crude) was obtained and the product yield was near 1OO H. The product was analyzed by ⁇ NMR (AC 200, CDC1 3 ).
- the product of the step holds physical and chemical data of m.p. -138 X(cjal, EtOH); IR(KBr):3600-3350, 2990, 1735, 1670, 1515, 1220, 1005cm "1 ;
- Example 3 The procedures of Example 1 were repeated, except that sodium iodide (0.96 g) was added to enhance reaction rates in exchanging halogens and to reduce the amount of by products and except that the first step of reaction lasted for 8.5 hours. The results showed that 40.7% of (l 'S,3S)-3- [(r-(ethoxycarbonyl)-3'-phenylpropyl)amino]-2,3,4,5-tetrahydro-2-oxo- lH-benzazepine and 41.4% of (l'S,3R)-3-[(l'-(ethoxycarbonyl)-3'- phenylpropyl)amino]-2,3,4,5-tetrahydiO-2-oxo- lH-benzazepine and 1O.2 H of side products were produced.
- Example 3 Example 3
- Example 1 The procedures of Example 1 were repeated, except that the phase transfer catalyst was replaced by (-)-N-dodecyl-N-methyl-ephedrinium bromide.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne un procédé de fabrication de 3-[(1'-(alkoxycarbonyl)-3'-phénylpropyl)amino]-2-oxo-[1]-benzazépine dont les dérivés sont des inhibiteurs de l'enzyme de conversion de l'angiotensine (ACE), utiles dans les traitements d'hypertension, de crise cardiaque chronique, et d'insuffisance rénale chronique progressive. Par l'utilisation d'un ester d'acide aminé non naturel, un ester d'alkyle de L-homophénylalanine, comme matériau clé de départ dans la condensation avec une 3-halo-2,3,4,5-tétrahydro-1H-1-benzazépine-2-one, qui peut être obtenue en quantités importantes, les procédés de la présente invention permettent d'éviter une racémisation, demandent moins d'étapes de procédures opérationnelles et sont plus pratiques et plus économiques que les procédés classiques.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2000239828A AU2000239828A1 (en) | 2000-04-18 | 2000-04-18 | Process for preparation of 3-((1'-(alkoxycarbonyl)-3'-phenylpropyl)amino)-2-oxo-(1)- benzazepine and its derivatives |
PCT/IB2000/000478 WO2001079176A1 (fr) | 2000-04-18 | 2000-04-18 | Procede de preparation de 3-[(1'-(alkoxycarbonyl)-3'-phenylpropyl)amino]-2-oxo-[1]-benzazepine et de ses derives |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2000/000478 WO2001079176A1 (fr) | 2000-04-18 | 2000-04-18 | Procede de preparation de 3-[(1'-(alkoxycarbonyl)-3'-phenylpropyl)amino]-2-oxo-[1]-benzazepine et de ses derives |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001079176A1 true WO2001079176A1 (fr) | 2001-10-25 |
Family
ID=11003908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2000/000478 WO2001079176A1 (fr) | 2000-04-18 | 2000-04-18 | Procede de preparation de 3-[(1'-(alkoxycarbonyl)-3'-phenylpropyl)amino]-2-oxo-[1]-benzazepine et de ses derives |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2000239828A1 (fr) |
WO (1) | WO2001079176A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104788376A (zh) * | 2014-01-17 | 2015-07-22 | 海门慧聚药业有限公司 | 一种盐酸贝那普利的新晶型及其制备方法 |
CN110835319A (zh) * | 2018-08-16 | 2020-02-25 | 湖南旭康医药科技有限公司 | 一种贝那普利中间体和贝那普利盐酸盐的合成方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4575503A (en) * | 1983-02-10 | 1986-03-11 | Ciba-Geigy Corporation | 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids |
US4600534A (en) * | 1984-02-06 | 1986-07-15 | Ciba-Geigy Corporation | Process and intermediates for manufacture of 3-(5-amino-1-carboxypentylamino)-tetrahydro-1-benzazepin-2-one-1-acetic acid |
US4785089A (en) * | 1985-06-13 | 1988-11-15 | Ciba-Geigy Corporation | Novel sulfonic acid esters and their preparation |
EP0903337A1 (fr) * | 1996-05-10 | 1999-03-24 | Kaneka Corporation | Procede de preparation de derives de 1-alcoxycarbonyl-3-phenylpropyle |
-
2000
- 2000-04-18 AU AU2000239828A patent/AU2000239828A1/en not_active Abandoned
- 2000-04-18 WO PCT/IB2000/000478 patent/WO2001079176A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4575503A (en) * | 1983-02-10 | 1986-03-11 | Ciba-Geigy Corporation | 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids |
US4600534A (en) * | 1984-02-06 | 1986-07-15 | Ciba-Geigy Corporation | Process and intermediates for manufacture of 3-(5-amino-1-carboxypentylamino)-tetrahydro-1-benzazepin-2-one-1-acetic acid |
US4785089A (en) * | 1985-06-13 | 1988-11-15 | Ciba-Geigy Corporation | Novel sulfonic acid esters and their preparation |
EP0903337A1 (fr) * | 1996-05-10 | 1999-03-24 | Kaneka Corporation | Procede de preparation de derives de 1-alcoxycarbonyl-3-phenylpropyle |
Non-Patent Citations (3)
Title |
---|
ATTWOOD M R ET AL: "THE DESIGN AND SYNTHESIS OF THE ANGIOTENSIN CONVERTING ENZYME INHIBITOR CILAZAPRIL AND RELATED BICYCLIC COMPOUNDS", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1,GB,CHEMICAL SOCIETY. LETCHWORTH, 1986, pages 1011 - 1019, XP000196065, ISSN: 1470-4358 * |
BEYER S K ET AL: "NOTIZ ZUR SYNTHESE EINES OPTISCH AKTIVES ACE-HEMMERS MIT AMINO-OXO-BENZAZEPIN-1-ALKANSAEURE-STRUKTUR MITTELS ENANTIOKONVERGIERENDER, KRISTALLISATIONSINDUZIERTER RACEMAT-TREMUNG", HELV CHIM ACTA, vol. 71, 1988, pages 337 - 343, XP000916421, ISSN: 0743-7463 * |
J W WATTHEY ET AL: "Synthesis and biological properties of (carboxyalkyl)amino-substituted bicyclic lactam inhibitors of angiotensin converting enzyme", JOURNAL OF MEDICINAL CHEMISTRY, vol. 28, no. 10, 1985, pages 1511 - 1516, XP000942750 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104788376A (zh) * | 2014-01-17 | 2015-07-22 | 海门慧聚药业有限公司 | 一种盐酸贝那普利的新晶型及其制备方法 |
CN110835319A (zh) * | 2018-08-16 | 2020-02-25 | 湖南旭康医药科技有限公司 | 一种贝那普利中间体和贝那普利盐酸盐的合成方法 |
CN110835319B (zh) * | 2018-08-16 | 2023-06-20 | 杭州馨佳源环保科技有限公司 | 一种贝那普利中间体和贝那普利盐酸盐的合成方法 |
Also Published As
Publication number | Publication date |
---|---|
AU2000239828A1 (en) | 2001-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101440257B1 (ko) | 약학적 활성 화합물의 제조에 사용되는 중간체의 제조 방법 | |
CN101993407B (zh) | 用于制备西洛多辛的吲哚啉化合物及其制备方法 | |
JP5254836B2 (ja) | ベナゼプリル及びその類似体の生産に有用な中間体の速度論的分離 | |
JP4048119B2 (ja) | 2−(4−クロロベンゾイルアミノ)−3−[2(1h)−キノールリノン−4−イル]プロピオン酸の製造方法 | |
US6743926B2 (en) | Process for the preparation of indole derivatives and intermediates of the process | |
WO2001025185A1 (fr) | Procede de production de derive de piperazine | |
US6458963B1 (en) | Process for preparing eprosartan using regioselective protection of 2,4-disubstituted-imidazole intermediates | |
WO2001079176A1 (fr) | Procede de preparation de 3-[(1'-(alkoxycarbonyl)-3'-phenylpropyl)amino]-2-oxo-[1]-benzazepine et de ses derives | |
AU2002354753A1 (en) | Kinetic resolution of a intermediate useful in the production of benazepril and analogues thereof | |
JP4433365B2 (ja) | 4−(2−メチル−1−イミダゾリル)−2,2−ジフェニルブタンアミドの製造方法 | |
CN113620869B (zh) | 一种贝曲西班的制备方法 | |
WO1998012186A1 (fr) | Procede de preparation d'ethers glycidyliques | |
JP5087059B2 (ja) | 4−(2−メチル−1−イミダゾリル)−2,2−ジフェニルブタンアミドの製造方法 | |
JP4426659B2 (ja) | 3,6−ビス置換アミノ−2,5−ピラジンジカルボニトリルの製造法 | |
JP2001131148A (ja) | ジアステレオマ−結晶の析出方法 | |
WO2007132990A1 (fr) | Procédé de préparation de glycidylphthalimide chirale de haute pureté optique, | |
US7214796B2 (en) | Process for production of 1-[2-(benzimidazol-2-yl-thio)ethyl]piperazine or salts thereof | |
JP2005531519A (ja) | セルトインドールの製造方法 | |
CN116804011A (zh) | 通过外消旋体拆分制备非奈利酮中间体的方法 | |
CN118047732A (zh) | 一种达比加群酯特殊中间体的制备工艺 | |
CN119431368A (zh) | 一种非奈利酮中间体及其制备方法和应用 | |
EP4375282A1 (fr) | Procédé de préparation d'un inhibiteur de la nucléocapside du virus de l'hépatite b | |
JP2017002008A (ja) | (3r,4s)‐1‐(4‐フルオロフェニル)‐[3(s)‐ヒドロキシ‐3‐(4‐フルオロフェニル)プロピル]‐[4‐(フェニルメトキシ)フェニル]‐2‐アゼチジノンの製造方法 | |
CN115043848A (zh) | 一种s-(+)-依托度酸甲酯的制备方法 | |
JP2001048845A (ja) | 光学活性1−フェニル−2−(p−置換フェニル)エチルアミン類の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |